Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U5FF
|
|||
| Former ID |
DAP000020
|
|||
| Drug Name |
Leuprolide
|
|||
| Synonyms |
Enantone; Eligard (TN); Leuprorelin (INN); Viadur (TN); 5-oxoprolylhistidyltryptophylseryltyrosylleucylleucyl-n5-(diaminomethylidene)ornithyl-n-ethylprolinamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0; ICD-10: C61; ICD-9: 185] | Approved | [1], [2] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Abbott Laboratories
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C59H84N16O12
|
|||
| Canonical SMILES |
CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6
|
|||
| InChI |
1S/C59H84N16O12/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64)/t40-,41-,42-,43+,44-,45-,46-,47-,48-/m0/s1
|
|||
| InChIKey |
GFIJNRVAKGFPGQ-LIJARHBVSA-N
|
|||
| CAS Number |
CAS 53714-56-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7979754, 14841815, 14890460, 14939438, 14939439, 24896252, 53788272, 76420344, 93815085, 104234343, 113529016, 123120929, 126659514, 135004318, 135610168, 135652260, 139293905, 152032163, 152344501, 160848497, 162177755, 162226920, 164831219, 175266671, 179150581, 179578146, 187072142, 223808168, 226396558, 245523766, 249719037, 251915682, 251917032
|
|||
| ChEBI ID |
CHEBI:6427
|
|||
| ADReCS Drug ID | BADD_D01261 | |||
| SuperDrug ATC ID |
L02AE02
|
|||
| SuperDrug CAS ID |
cas=053714560
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leutinizing-hormone-releasing hormone (GNRH1) | Target Info | Activator | [2] |
| KEGG Pathway | GnRH signaling pathway | |||
| Pathway Interaction Database | Nongenotropic Androgen signaling | |||
| Reactome | Hormone ligand-binding receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Gastrin-CREB signalling pathway via PKC and MAPK | |||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1175). | |||
| REF 2 | Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy. 2008 Dec;28(12):1511-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.